About MS Views and News
Within this blog you will find thousands of valuable MS related articles and resources which will enable you to learn and feel empowered with key Multiple Sclerosis information.
From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.
Be empowered with MS news. CLICK HERE -to Subscribe forThe MS BEACON eNewsletter
Plus, learn from the MS Views and News Learning Channel on YouTube: www.youtube.com/msviewsandnews:
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Saturday, April 16, 2011
|MS-STEUNACTIE loopt van 14 januari tot 25 mei 2011 / MS SUPPORT ACTION runs from 14.JAN. TILL 25.MAY|
PLEASE NOTICE: For organizational reasons we ask those who are really coming to Brussels to fill out the form . Thanks for this.
GOAL OF THIS ACTION: MS SUPPORT ACTION : RUNS FROM 14 JANUARY UNTILL 25 MAY (MS WORLDDAY)
What has been achieved up to now:
12.30 :a.p. meeting Alexander De Croo
10 : a.p. meeting Etienne Schou
25 May (so far):
11:a.p. meeting Jo Vandeurzen (Flemish Parliament)
13.30:a.p. meeting Fadila Laanan
14:a.p. meeting Delizée
14:30 p.m. meeting with Elio Di Rupo
16:30 p.m. meeting with Petru Luhan (European Parliament)
Goal of this action :
You may know someone with MS. Or maybe you see yourself day in day out confronted with MS. In either case SUPPORT this action.
MS is a disease that although not always visible gradually makes it impossible for the patient to function normally - physically as well as mentally. MS starts in the brain. It then progressively attacks the nervous system. As it spreads throughout the body, the patient's gait, balance, and vision deteriorate irreversibly. In the end the patient finds himself increasingly disabled and largely dependant on another person's help.
Belgium lags behind in its fight against MS and the impact it has - socially and financially - on the patient's life. There is no national register. Financial support remains insufficient. Not enough coverage from the media.
In order to focus public attention on this devastating disease I started this action (together with my daughter Isabella - see her picture on this page).
How to support this action:
Either visit the page on Facebook and express your support
Or Leave some comment in the guestbook on this site.
The pressure must increase!
All reactions will be collected in a file. This file will be handed over to our national and European policy making authorities in Brussels on 25th of May, world MS day 2011.
The more numerous we are, the more successful our trip to Brussels will be. A special appeal to those who cannot come to Brussels: if you cannot be there please leave some words of sympathy in support of our action on the Facebook Page.
This action runs from 14 January until 25 May 2011. From the 15th of May onwards all modalities will be worked out and communicated.
Isa tells about MS - movie (Dutch spoken)
FRIDAY, April 15 (HealthDay News) -- The immunomodulator laquinimod appears to reduce the relapse rate and delay the progression of disability in individuals with multiple sclerosis (MS), according to research presented at the annual meeting of the American Academy of Neurology, held from April 9 to 16 in Honolulu.
In the ALLEGRO trial, Giancarlo Comi, M.D., of the Scientific Institute and University Vita-Salute San Raffaele in Milan, Italy, and colleagues randomized 1,106 people with relapsing-remitting MS in 24 countries to receive either a once-daily oral dose of 0.6 mg of laquinimod or a matching placebo for two years.
The researchers found that 80 percent of individuals who received laquinimod and 77 percent of those who took placebo completed the two-year study. Compared to patients who received placebo, individuals treated with laquinimod experienced a significantly lower annual relapse rate -- a 23 percent reduction. Treatment with laquinimod was associated with a 36 percent reduction in disability progression and a 32.8 percent reduction in the progression of brain atrophy (P < 0.0001). The investigators also found that adverse events and serious adverse events were similar between the two groups.